Core Viewpoint - New Bridge Bio has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors [1] Company Overview - New Bridge Bio, established in 2016, is a global biotechnology platform company focusing on developing innovative precision immuno-oncology drugs for cancer treatment [4] - The company aims to enhance its pipeline through strategic collaborations and specialized subsidiaries to better seize market opportunities [4] Product Development - The core product, givastomig, is a novel bispecific antibody targeting Claudin18.2 (CLDN18.2) and T-cell co-stimulatory molecule 4-1BB, applicable to various gastrointestinal malignancies [5] - Givastomig has two main advantages: it can effectively bind to tumors with low CLDN18.2 expression and activates T-cells only after binding to tumor cells, minimizing systemic side effects [5] Market Potential - According to Frost & Sullivan, the global market size for first-line treatments of GEA, BTC, and PDAC (excluding Greater China and South Korea) is estimated at $8.9 billion, $1.8 billion, and $4.4 billion respectively in 2024, projected to reach $13 billion, $2.9 billion, and $6.4 billion by 2034 [7] Clinical Development - New Bridge Bio has completed the safety assessment of the Phase I clinical study and plans to initiate a randomized Phase II study in early 2026 [7] - The company has established a pipeline that includes three clinical-stage projects, with givastomig being a key focus [7] Financial Performance - For the fiscal year ending December 31, 2023, New Bridge Bio reported total revenues of approximately -$202.12 million, with significant operating losses [8] - The company’s total expenses for 2023 were approximately $72.65 million, leading to a substantial operating loss of $72.02 million [8]
新股消息 | 新桥生物递表港交所 主要专注于开发自主研发的创新型精准免疫肿瘤药物
Zhi Tong Cai Jing·2025-10-30 23:29